下颌前移装置与联合气道及体位疗法治疗鼾症的随机临床试验
这项在学术医疗中心开展的初步随机临床试验,将50对打鼾且无睡眠呼吸暂停的受试者及其伴侣随机分配至下颌前移装置(MAD)组或联合气道及体位疗法(CAPT)组,治疗4周。42对完成研究,MAD组伴侣报告鼾声改善的应答率为91%,CAPT组为58%,差异33个百分点(95%CI 8-58)。结论认为MAD可能比CAPT更有效,但两者均能减轻原发性鼾症。
要点
- MAD组伴侣报告鼾声改善的应答率为91%,CAPT组为58%,差异33个百分点(95%CI 8-58)。
- 两种治疗均能减轻原发性鼾症,MAD可能比CAPT更有效。
- 医生应与患者进行以患者为中心的讨论,权衡便利性、不良反应和费用。
核心结论
- MAD可能比CAPT更有效治疗原发性鼾症,但两种治疗均能减轻原发性鼾症。
- 医生应与患者进行以患者为中心的讨论,权衡便利性、不良反应和费用,以确定最适合个体患者的治疗。
研究设计与样本
- 初步随机临床试验,在学术医疗中心开展,纳入打鼾且无睡眠呼吸暂停的便利样本及其同床伴侣,治疗4周。
- 50对伴侣随机分配至MAD组或CAPT组,最终42对完成研究,其中MAD组23对(55%),CAPT组19对(45%)。
- 打鼾者中26人(62%)为女性,平均(SD)年龄48(14)岁。
主要发现
- MAD组23对中21人(91%)被伴侣评为应答者,CAPT组19对中11人(58%)被伴侣评为应答者,差异33个百分点(95%CI 8-58),需治疗人数为3。
- 10例退出者中,4例因治疗不良反应退出,MAD组和CAPT组各2例。
关键数值与推荐
- 主要结局为伴侣报告打鼾在临床总体印象改善量表上为非常改善或很大改善的百分比(应答者)。
- MAD组应答率91% vs CAPT组58%,差异33个百分点(95%CI 8-58)。
- 需治疗人数为3。
临床怎么用
- 作者认为MAD可能比CAPT更有效治疗原发性鼾症,两种治疗均能减轻原发性鼾症。
- 作者建议医生与患者进行以患者为中心的讨论,权衡便利性、不良反应和费用,以确定最适合个体患者的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately 150 million individuals in the US snore in the absence of obstructive sleep apnea (primary snoring), but few studies have examined the efficacy of treatments for snoring or evaluated the effect of snoring in sleeping partners. OBJECTIVE: To evaluate the efficacy of 2 treatments for primary snoring. DESIGN, SETTING, AND PARTICIPANTS: This pilot randomized clinical trial that included a convenience sample of people who snore without sleep apnea and their sleeping partner who underwent 4 weeks of snoring treatment was conducted at an academic medical center between October 3, 2022, and July 3, 2023. INTERVENTIONS: Fifty couples were randomized to either use a mandibular advancement device (MAD) or receive combined airway and positional therapy (CAPT; external nasal dilator, nasal saline lavage with mometasone, mouth taping, and lateral positional therapy). MAIN OUTCOME AND MEASURE: Percentage of sleeping partners who reported that their partner's snoring was either very much improved or much improved (responder) on the Clinical Global Impression of Improvement scale. RESULTS: A total of 42 dyads completed the study; 23 (55%) were randomized to MAD and 19 (45%) to CAPT. Among people who snore, 26 (62%) were female, and the mean (SD) age was 48 (14) years. Of 23 dyads randomized to MAD, 21 people who snore (91%) were rated by the sleeping partner as a responder, while 11 of the 19 dyads (58%) randomized to CAPT were rated by the sleeping partner as responder, resulting in a difference of 33 percentage points (95% CI, 8-58) and a number needed to treat of 3. Of the 10 participants who were withdrawn, 4 were withdrawn due to adverse effects of the treatment that were evenly distributed between the MAD (n = 2) and CAPT (n = 2) groups. CONCLUSION AND RELEVANCE: The results of this randomized clinical trial showed that the MAD may be more effective than CAPT for treating primary snoring, while both treatment options were found to reduce primary snoring. Physicians should have a patient-centered discussion to determine which treatment is best for individual patients with primary snoring, weighing convenience, adverse effects, and cost as factors. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05756647.
引用
- Ioerger P, Afshari A, Hentati F, et al. Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38780959. doi:10.1001/jamaoto.2024.1035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。